MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Начало・Списък с акции・Pulse Biosciences Inc

Pulse Biosciences Inc

Затворен

СекторЗдравеопазване

13.75 -3.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.75

Максимум

14.24

Ключови измерители
By Trading Economics
Приходи	-217K -19M
Продажби	86K 86K
EPS	-0.29
Марж на печалбата	-22,540.698
Служители	75
EBITDA	-228K -19M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+54.39% upside

Дивиденти
By Dow Jones
Следващи печалби	26.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-179M 958M
Предишно отваряне	17.19
Предишно затваряне	13.75

Настроения в новините

By Acuity

60%

40%

312 / 361 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.59 / 17.17 Подкрепа & съпротива

Pulse Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.01.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Consolidates; May Face Technical Correction -- Market Talk

20.01.2026 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20.01.2026 г., 23:41 ч. UTC

Печалби

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20.01.2026 г., 23:29 ч. UTC

Пазарно говорене

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20.01.2026 г., 23:26 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.01.2026 г., 23:26 ч. UTC

Пазарно говорене

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20.01.2026 г., 22:45 ч. UTC

Придобивния, сливания и поглъщания

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20.01.2026 г., 22:45 ч. UTC

Придобивния, сливания и поглъщания

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20.01.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20.01.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20.01.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20.01.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20.01.2026 г., 22:27 ч. UTC

Придобивния, сливания и поглъщания

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20.01.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20.01.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20.01.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20.01.2026 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20.01.2026 г., 22:18 ч. UTC

Печалби

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20.01.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20.01.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20.01.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20.01.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20.01.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20.01.2026 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20.01.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20.01.2026 г., 22:08 ч. UTC

Придобивния, сливания и поглъщания

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20.01.2026 г., 22:07 ч. UTC

Придобивния, сливания и поглъщания

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20.01.2026 г., 22:06 ч. UTC

Печалби

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20.01.2026 г., 22:00 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

ESG Roundup: Market Talk

20.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pulse Biosciences Inc Прогноза

Ценова цел

By TipRanks

54.39% нагоре

12-месечна прогноза

Среден 22 USD 54.39%

Висок 22 USD

Нисък 22 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Pulse Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Pulse Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.59 / 17.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Настроение

By Acuity

312 / 361 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.